| Literature DB >> 28634614 |
Mamiko Sakata-Yanagimoto1,2, Rie Nakamoto-Matsubara3, Daisuke Komori3, Tran B Nguyen3, Keiichiro Hattori3, Toru Nanmoku4, Takayasu Kato5,6, Naoki Kurita5,6, Yasuhisa Yokoyama5,6, Naoshi Obara5,6, Yuichi Hasegawa5,6, Atsushi Shinagawa7, Shigeru Chiba8,9.
Abstract
Recent genetic studies identified that the disease-specific G17V RHOA mutation, together with mutations in TET2, DNMT3A, and IDH2, is a hallmark of angioimmunoblastic T cell lymphomas (AITL). The diagnostic value of these mutations is now being investigated. Circulating tumor DNAs (ctDNAs) may offer a non-invasive testing for diagnosis and disease monitoring of cancers. To investigate whether these mutations are useful markers for ctDNAs in AITL and its related lymphomas, we performed targeted sequencing for TET2, RHOA, DNMT3A, and IDH2 in paired tumors and cell-free DNAs from 14 patients at diagnosis. Eighty-three percent of mutations detected in tumors were also observed in cell-free DNAs. During the disease course, mutations were detectable in cell-free DNAs in a refractory case, while they disappeared in a chemosensitive case. These data suggest that the disease-specific gene mutations serve as sensitive indicators for ctDNAs and may also be applicable for non-invasive monitoring of minimal residual diseases in AITL.Entities:
Keywords: AITL; Cell-free DNA; RHOA; TET2; ctDNA
Mesh:
Substances:
Year: 2017 PMID: 28634614 DOI: 10.1007/s00277-017-3038-2
Source DB: PubMed Journal: Ann Hematol ISSN: 0939-5555 Impact factor: 4.030